Brief Article
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Feb 14, 2009; 15(6): 727-731
Published online Feb 14, 2009. doi: 10.3748/wjg.15.727
Table 1 Classification of endoscopic findings according to the Lanza score[5]
ScoreEndoscopic findings
0No lesion
1Hemorrhagic erosion
2One or two erosions
33-10 erosions
4More than 10 erosions
5Ulcer
Table 2 Anti-ulcer drugs used in patients enrolled in study-1
Type of drugDrug nameDoses (/day)Number of patients
None34
PPIs8
Rabeprazole sodium10 mg3
Lansoprazole30 mg2
Lansoprazole15 mg1
Omeprazole20 mg2
H2RAs16
Famotidine40 mg1
Famotidine20 mg8
Famotidine10 mg1
Lafutidine20 mg2
Nizatidine300 mg2
Ranitidine hydrochloride75 mg1
Cimetidine100 mg1
Cytoprotective anti-ulcer drugs10
Rebamipide300 mg2
Rebamipide200 mg1
Rebamipide100 mg1
Azulensulfonate sidium + L-Glutamine2 g2
Teprenone1.5 g1
Polaprezinc150 mg1
Sofalcone300 mg1
Alginate sodium180 mL1
Table 3 Endoscopic findings classified according to the Lanza score in patients receiving low-dose aspirin with or without anti-ulcer drugs
Number of patientsSex M:FAge (yr)(mean ± SD)Lanza scores (Number of patients)
Mean scores
012345
No anti-ulcer drugs
3424:10:0069.4 ± 11.210101314.741
Cytoprotective drugs
108:0267.9 ± 8.61001084.301
H2RAs
167:0967.8 ± 14.07310051.881
At regular doses
52:0369.6 ± 10.82110011.601
Less than regular doses
115:0666.9 ± 15.65200042.001
PPIs
86:0262.0 ± 17.06001011.001